Journal article
Ilodecakin. Schering-Plough Corp.
Abstract
Schering-Plough's interleukin (IL)-10 (ilodecakin) is under investigation for the potential treatment of autoimmune diseases, solid tumors, ulcerative colitis, Crohn's disease and organ transplantation. In June 1996, ilodecakin entered phase II trials for Crohn's disease, ulcerative colitis and rheumatoid arthritis and, as of June 1999 was reported to be in phase III trials for Crohn's disease and rheumatoid arthritis. It has also demonstrated …
Authors
Marshall JK
Journal
IDrugs, Vol. 2, No. 10, pp. 1045–1058
Publication Date
October 1999
ISSN
1369-7056